[Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents; D001053:Apolipoproteins / Q000037:antagonists & inhibitors; D001055:Apolipoproteins B; D001629:Bezafibrate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000037:antagonists & inhibitors
D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D001055:Apolipoproteins B; D008055:Lipids; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D001629:Bezafibrate
Wpływ bezafibratu na lipidy i lipoproteiny osocza oraz poziom apoproteiny B u chorych z typem II I IV hiperlipoproteinemii.